Preserving Access To Essential Medications: Opposing Changes To Medicare Part D's Protected Classes.pdf

Azar II, regarding a proposed rule (CMS-4180P) aiming to modernize Medicare Part D and Advantage plans to reduce drug prices and out-of-pocket expenses.

Key Points:

The letter argues against significant changes to the "six protected classes" policy within Medicare Part D, which ensures coverage for specific high-need drugs (anticonvulsants, antidepressants, etc.) used by vulnerable beneficiaries.

Concerns:

1. Prior Authorization Requirements: The proposal allows Step Therapy and other prior authorization requirements on protected class drugs, potentially leading to:
- Delays in treatment and medication noncompliance.
- Increased administrative costs for providers.
- Poorer health outcomes due to reduced adherence.

2. Limited Access to Treatments: Even with existing policies, Part D plans already have restrictive formularies for these classes compared to commercial insurance. The proposal could further limit access to necessary treatments, especially within large drug categories.

3. Burdened Appeals Process: The letter highlights the already flawed Medicare appeals process and expresses concern that proposed changes will increase appeals and exceptions, adding to existing burdens.

4. Impeded Access to New Drugs: CMS' proposal would allow Part D sponsors to exclude new formulations of protected class drugs if a manufacturer introduces a different version with the same active ingredient, potentially hindering access to medical breakthroughs.

Call to Action:

The undersigned organizations urge Secretary Azar to not finalize the proposed changes, emphasizing the potential negative impact on vulnerable patients and their access to essential medications.